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Abstract
Insulinoma is a rare pancreatic endocrine tumour and is typically sporadic and solitary. Over 90%
of all insulinomas are benign. Cystic insulinomas are also rare. It is not difficult to determine the
site of such neoplasm, as cystic insulinomas are usually 4–10 cm in diameter. We present the case
of a patient with a histologically confirmed cystic insulinoma diagnosed after approximately 10 years
of hypoglycaemia symptoms. This case is unique because of the small size (2.2 cm) of the tumour.
Endoscopic ultrasound (EUS) was useful for localizing this tumour.
Introduction
Pancreatic endocrine tumors are rare lesions, with a
reported incidence of four cases per 1 million patients a
year [1]. Of these lesions, insulinomas are the most com-
mon. The majority of patients diagnosed with an insuli-
noma are between 30 and 60 years of age, with women
accounting for 59 % of cases [2,3]. Most insulinomas are
sporadic in their origin. They are more likely to be multi-
ple in patients with multiple endocrine neoplasia type I
[1,4]. Pancreatic neuroendocrine tumors rarely manifest
cystic changes [5]. Cystic neuroendocrine tumors are dif-
ficult to diagnose preoperatively because the majority of
these tumors are non-functional, and computerized
topography (CT) does not differentiate these tumors from
other cystic neoplasms. Cystic neuroendocrine tumors
represent a subgroup of pancreatic cystic and neuroendo-
crine tumors with malignant potential. Their high resecta-
bility rate further supports the role of surgical exploration
and resection in the treatment of a pancreatic cystic neo-
plasm [6]. Insulinoma tumors are often difficult to detect
as the symptoms largely precede occurrence of a visual-
ized tumor [3]. Cystic insulinomas are rare, with only a
few cases having been reported in the literature [6].
In our case report we point out the difficulties in diagnos-
ing a small cystic insulinoma. Diagnosis of insulinoma
could be difficult if the functional activity is incomplete,
possibly leading to blunted symptoms of hypoglycemia.
Our case shows the usefulness of endoscopic ultrasound
for localizing a small cystic tumor from other pancreatic
lesions.
Case presentation
A 51-year-old male (BMI 27.5 kg/m2) was admitted to
hospital due to recurrent episodes of confusion, light-
headedness, chills, palpitations and shakiness for more
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than eight years. He typically experienced these symptoms
after extensive physical activities.
The patient's past medical history indicated hypertension
and he was taking an ACE inhibitors. There was about a
history of alcohol abuse in the past. There was no family
history of hyperparathyroidism, ulcer disease or hypogly-
caemia, but his father had had hypertension.
He underwent a 72 hour-fast test, interrupted after 36
hours due to neuroglycopenic symptoms (plasma glucose
2.4 mmol/l, insulin 21.1 mU/l (n.r. 1–20 mU/l), C-pep-
tide 1.5 nmol/l (n.r. 0.3–0.7 nmol/l)). During the course
of the fasting his blood was checked with GC-MS (Gas/
Mass Chromatography) for oral hypoglycaemic drugs and
was positive on tolbutamide. Both he and his family
denied any intake of oral antidiabetic preparations, but
there were no further hypoglycaemia attacks in subse-
quent days in the hospital.
One year later, during a second episode of hospitaliza-
tion, the test on tolbutamide during the 72 hour-fast was
repeated and the result was negative. This time the fasting
was interrupted after 8 hours (plasma glucose 1.8 mmol/
l, insulin 16.3 mU/l). C-peptide suppression test [7]
showed good suppression of C-peptide (46%). Abdomi-
nal ultrasound, magnetic resonance imaging (MRI) and
EUS were negative. He refused surgical exploration of the
pancreas and on that occasion he was prescribed diazox-
ide. He started the treatment but terminated it after a
while on his own accord. In the meantime between the
second and the third episodes of hospitalization three
years later, he experienced hypoglycaemia symptoms with
similar frequency and his health insurance sent him back
to hospital for further assessment after a car incident.
During his latest hospital visit, a 72 hour-fast test was
interrupted on the first day after 5 hours (glucose 1.5
mmol/l, insulin 31.4 mU/l, C-peptide 2.1 nmol/l). This
time C-peptide suppression test was in favour of autono-
mous insulin secretion: 30 minutes 3.53% suppression,
60 minutes 3.83% suppression, 90 minutes 20% suppres-
sion. MRI was again negative. A selective pancreatic arteri-
ography showed a focal avascular lesion in the body of the
pancreas near the tail. EUS confirmed a lesion in the pan-
creatic body near the tail and no other lesions. It was a
cystic lesion measuring 2.28 cm in diameter with a very
thick wall measuring 3–4 mm (Figure 1).
He was operated on and a 2.5 × 2 × 2 cm well bounded
tumour, weighing 4 grams, was removed from the pan-
creas body (Figure 2). There was no evidence of gross inva-
sion, abnormal lymph nodes or liver metastases.
Pathological evaluation revealed a well differentiated
insulinoma with fibrous connective tissue and cystic for-
mation of 8 mm in diameter in the middle of the tumour.
The tumour consisted of small nests of homogeneous,
cylindrical tumour cells without any cytological atypia,
mitotic activity or necrosis. Immunohistochemical stain-
ing confirmed the diagnosis of insulinoma (Fig 3). Seven
days after the operation, the patient was discharged with
Postoperative finding: 2.5 × 2 × 2 cm well bounded tumour,  weighing 4 grams, cystic formation of 8 mm in diameter in  the middle of the tumour Figure 2
Postoperative finding: 2.5 × 2 × 2 cm well bounded tumour, 
weighing 4 grams, cystic formation of 8 mm in diameter in 
the middle of the tumour.
Endoscopic ultrasonography showing a cystic tumour in the  pancreatic body (Olympus GIF-130 video echo-endoscope  with 7.5/12 MHz switchable radial probe) Figure 1
Endoscopic ultrasonography showing a cystic tumour in the 
pancreatic body (Olympus GIF-130 video echo-endoscope 
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normal glucose profiles. Ten months after the operation
the patient is still free of the previous symptoms.
Discussion
This is a report of a patient with an unusual course of dis-
ease which was contributed to by a falsely positive test for
tolbutamide probably due to an insufficiently precise
method used to determine the presence of sulphonylurea
medications. It is also likely that the chronic course of this
disease is the consequence of the small size of the tumour.
Insulinoma tumours are often difficult to detect as the
symptoms largely precede occurrence of a visualizable
tumour [8]. In the case of this patient, all three fasting
tests were positive although the time of the interruption
was shortened over time. C-peptide suppression test could
have been helpful but in our case on two occasions we
obtained two different results [7]. Cystic endocrine
tumours of the pancreas rarely occur, and only a few cases
of cystic insulinomas have been reported to date [9]. Diag-
nosis of insulinoma could be difficult if the functional
activity is incomplete, possibly leading to blunted symp-
toms of hypoglycaemia and failure of laboratory investi-
gations to provide evidence of hyperinsulinemia [8]. A
clinical case of cystic insulinoma was recently reported by
histological examination after surgery, characterized by a
high intracystic insulin concentration despite normal
blood basal levels of the hormone [10]. In that case it was
suggested that cystic formation within a solid endocrine
neoplasm may be due to haemorrhage and necrosis of
tumour cells with disruption of tissue planes, leading to
cyst development [11] or that these slow-growing
tumours develop a fibrous capsule, which eventually
decreases the blood supply to the tumour leading to inf-
arction and liquefaction necrosis [11]. The evolution of
cysts can occur in small tumours and suggests that haem-
orrhage may be the inciting event.
Generally ultrasound (US), CT, angiography and transhe-
patic portal venous sampling (THPVS) have been widely
used in the preoperative localisation of such tumours with
various rates of accuracy of localisation reported by inves-
tigators [12]. The results of non-invasive-imaging tech-
niques, in general, have been discouraging. Sensitivities
ranging from 9 to 63% and from 16 to 72% have been
reported for US and CT scanning, respectively [12].
Higher sensitivity (ranging from 36 to 91%) has been
reported for angiography [12]. The best results have been
obtained by THPVS along the pancreatic vein: a sensitivity
of 82% and a specificity of 91% were reported by Vinik
[13]. Some centres use preoperative endoscopic ultra-
sound which has reported accuracy rates of 60–90% [14].
Lesions in the tail of the pancreas may be missed using
endoscopic ultrasound; however, these lesions are usually
easily identified intraoperatively [14]. Approximately,
40% of all insulinomas are not localised preoperatively,
and between 3 and 10% remain occult even after intraop-
erative palpation and the use of intraoperative ultrasound
(3,4). Portal venous sampling was not necessary preoper-
atively, even in the case of occult insulinoma. This inva-
sive technique, although helpful, cannot give precise
anatomical localisation and indicates only the region of
the pancreas from which the excess insulin secretion ema-
nates [13]. Localisation of an insulinoma with laparo-
scopic ultrasonography has also been reported [15].
Some authors consider endoscopic ultrasonography
(EUS) to be the single most important preoperative local-
isation study needed [15]. EUS allows high resolution
imaging of the pancreas [15]. It is accurate for pre-opera-
tive localization of pancreatic neuroendocrine tumours,
mainly insulinomas, and it is a good alternative to other
more invasive methods. The images of the inner structure
Insulinoma Figure 3
Insulinoma. Acini of exocrine pancreas (in the upper left cor-
ner), Haematoxylin-eosin, 60× (A). Insulinoma. Chrom-
ogranin A, 200× (Mild to moderate immunopositivity 
generally and scattered cells with intense immunopositivity. 
Strongly immunopositive cells of islet of Langerhans in the 
surrounding tissues) (B).
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of cystic lesions that this modality provides are not only
more accurate, but also displayed in fine detail [14].
However, the differential diagnosis of cystic pancreatic
lesions by EUS is still very difficult. Although fasting tests
confirmed autonomous insulin secretion in our patient,
angiography finding of a vascular area in pancreas did not
indicate that the EUS visualized cystic tumour in the pan-
creas was an insulinoma.
Conclusion
The differential diagnosis of cystic pancreatic lesions by
EUS is still very difficult. Although fasting tests confirmed
autonomous insulin secretion in our patient, the angiog-
raphy finding of a vascular area in the pancreas did not
indicate that te EUS visualized cystic tumour in the pan-
creas was an insulinoma. In our case report we point out
the difficulties in diagnosing a small cystic insulinoma if
the functional activity is incomplete, possibly leading to
blunted symptoms of hypoglycaemia. As far as we know
this is one of the few reported cases of a small cystic insuli-
noma. Our case shows the usefulness of endoscopic ultra-
sound for localizing small cystic pancreatic tumors.
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